Organon & Co.

Organon and Co. (NYSE: OGN - Get Free Report) and CASI Pharmaceuticals (NASDAQ: CASI - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk. Earnings and Valuation This table compares Organon

Organon (OGN) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $1.01 per share a year ago.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Announces Quarterly Dividend.

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its third quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (“SEC”). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the third quarter 2026, which will be.

Organon and Co. (NYSE: OGN - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Institutional and Insider Ownership 77.4% of Organon

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports positive interim Phase 3 results for MIUDELLA®, a hormone-free IUD, through 6 years of use with no new safety signals.

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.

VANCOUVER, BC / ACCESS Newswire / October 13, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce that it has signed a purchase and sale agreement (the "Agreement") with a subsidiary of Seabridge Gold Inc. ("Seabridge") whereby Seabridge will acquire a 100% interest in Orogen's Slaughterhouse Iron-Oxide-Copper-Gold ("IOCG") project in Wyoming, USA. Under the terms of the Agreement, Seabridge will pay to Orogen US$300,000 cash on closing and mil…

VANCOUVER, BC / ACCESS Newswire / October 8, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce that it has signed a purchase and sale agreement (the "Agreement") with Northern Discovery Metals (CSE:NOR) ("Northern") whereby Northern will acquire a 100% interest in the Cibola copper-gold porphyry project in British Columbia, Canada. Under the terms of the Agreement, Northern will pay to Orogen $130,000 and issue 700,000 common shares of Northe…

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to unveil first large-scale real-world effectiveness analyses of VTAMA (tapinarof) cream, 1% in patients with eczema at Fall Clinical.

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Organon and Co. (NYSE: OGN) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 56,850 shares of the company's stock, valued at approximately $770,000. A number of other hedge funds and other institutional investors

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces FDA accepts MIUDELLA® sNDA for review, seeking to extend approved hormone-free IUD use from 3 to 6 years in the U.S.

VANCOUVER, BC / ACCESS Newswire / September 10, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce the acquisition of the Serpent gold project in Nevada, USA. Project Highlights Serpent is a district scale, low-sulphidation epithermal gold target located in central Nevada Focused on a series of gold-bearing structures within an eight-kilometre trend of alteration Highly anomalous gold in rocks (up to 0.95 grams per tonne ("g/t") gold) associat…

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

VANCOUVER, BC / ACCESS Newswire / September 2, 2026 / Orogen Royalties Inc. ("Orogen" or the "Company") (TSXV:OGN)(OTCQX:OGNNF) is pleased to announce the acquisition of the Toro de Oro and El Gigante gold projects in Southwest Utah, USA. Project Highlights Two low-sulphidation epithermal targets located in caldera complexes of southwest Utah Toro de Oro is centered on an extensive footprint of steam cap alteration and chalcedonic vein sets indicating the high-level expression of an epithermal s…

Bank of America Corp DE reduced its position in shares of Organon and Co. (NYSE: OGN) by 58.5% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 738,502 shares of the company's stock after selling 1,041,346 shares during the period. Bank of America

TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Women's Health Collective Canada (WHCC) and the Partnership for Women's Health Research Canada (PWHR), in partnership with GreenShield and supported by a charitable grant from Organon, have launched the Researching Information, Support, and Equity During the Menopause Transition in Canada (Can-RISE) Study. As the first national investigator-led study focused on Canadian women's experiences of menopause and the menopausal transition, Can-RISE is led by P…